SEC Form 3 · accession 0001231919-26-000697
Solid Biosciences Inc. · SLDB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
RA Capital Healthcare Fund LP
10% Owner
RA CAPITAL MANAGEMENT, L.P.
10% Owner
Peter Kolchinsky
10% Owner
Rajeev M. Shah
10% Owner
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 6:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001707502
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | holding | — | — | — | 11,897,896 | I | See footnotes | |
| Common StockF1,F3 | holding | — | — | — | 109,661 | I | See footnotes | |
| Common StockF1,F4 | holding | — | — | — | 28,569 | I | See footnotes |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-Funded Warrants (Right to Buy)F1,F2,F5 | $0.001 | holding | — | — | — | — | — | Common Stock | 8,178,412 | — | I |
Explanation of responses
- F1RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- F2Held directly by the Fund.
- F3Held directly by the Nexus Fund.
- F4Held directly by the Account.
- F5The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.